Compare Citius Pharmaceuticals Inc (CTXR) vs FirstEnergy Corp. (FE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs FirstEnergy Corp. — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.79M), while FirstEnergy Corp. trades at $44.9 (market cap $25.80B). The key difference: FirstEnergy Corp. is far larger — about 1870.9× Citius Pharmaceuticals Inc's market cap, and FirstEnergy Corp. pays a 4.17% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and FirstEnergy Corp. for 71 Days on average.
| CTXR | FE | |
|---|---|---|
Market Cap | $13.79M | $25.80B |
Volume | 156,684 | 5,328,616 |
Sector | Health | Utilities |
52-Week High | $1.82 | $51.91 |
52-Week Low | $0.48 | $43.04 |
Typical Hold Time | 16 Days | 71 Days |
Enterprise Value | $3.96M | $54.72B |
Dividend Yield | — | 4.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, but remains in a bearish technical trend with negative profitability metrics. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR sales, though net income margin remains deeply negative at -651.27%. Analyst consensus is strongly bullish with 5 buy ratings and a $5.00 price target, representing significant upside potential from current levels.
While CTXR shows promising commercial progress with its oncology drug launch, the stock faces substantial execution risks due to persistent losses and cash burn. The bullish analyst sentiment contrasts with weak fundamentals, creating a high-risk, high-reward scenario for investors betting on successful commercialization of LYMPHIR in the $400M+ CTCL market.
FirstEnergy (FE) trades at $44.85, up 1.33% with mixed technical signals showing bullish overall but bearish moving averages. The company reported Q1 2026 EPS beat but missed Q4 2025 and Q2 2026 expectations, with Q3 2026 results pending. Revenue grew to $15.09B in 2025 with stable profit margins around 6.86%. Recent developments include the $36B Energize365 investment plan and consistent dividend payments, supporting long-term growth prospects in the utility sector.
FE presents a moderate buy opportunity with analyst consensus target of $52.80 offering 17.7% upside. Strong institutional interest and dividend stability balance execution risks from heavy capital expenditures and debt levels. The stock's valuation appears reasonable with P/E of 23.84, though investors should monitor earnings consistency and regulatory developments in the electric utility space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →
